Recce Ltd has released a press release.
Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort
- MCRI Pilot Study- Positive Efficacy Data for Lung Infections
- China Patent Granted for RECCE Anti-Infectives
- Safety Committee Approves High Dose of 4,000mg
- Recce Completes 5,000 R327 Doses Per Week under GMP
Later from Recce Pharmaceuticals
- R327 added to WHO List of Antibacterial Products
- Further R&D Rebate Approved
- Ethics Approval Broadens to All Topical Infections
- Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
- Placement & SPP to raise $10 million - Funded to FY26
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals